EIF4EBP1 and prostate carcinoma: For instance, dual PI3K/mTOR inhibitors such as omipalisib (GSK2126458/GSK458), gedatolisib (PKI-587), and dactolisib (BEZ235) have been shown to effectively suppress the phosphorylation of mTOR, AKT, and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) in NPC and prostate cancer cells.